C
Centrexion Therapeutics
Relieve the suffering associated with chronic pain
About Centrexion Therapeutics
A late clinical-stage biopharmaceutical company focused on developing and commercializing non-opioid, non-addictive therapies for chronic pain. The company's lead product candidate, CNTX-4975, is a synthetic form of trans-capsaicin injected directly into the site of pain, and is being developed for the treatment of chronic moderate to severe pain from knee osteoarthritis.
The company's business model is to identify, develop and commercialize new therapies for pain. This includes conducting clinical trials to establish the safety and efficacy of its drug candidates, and then seeking regulatory approval to market and sell them. The company also enters into strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its products. For example, Eli Lilly has licensed CNTX-0290, a somatostatin receptor type 4 (SSTR4) agonist, from Centrexion.
The company operates in the pain management market, which is a large and growing market with a significant unmet need for safe and effective non-opioid pain therapies. Its clients are patients with chronic pain, and its customers are healthcare providers who prescribe its products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Boston, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 68.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Surgery, Chronic Disease, Spinout, Biotech and Pharma, DT and LS, science-based
- Technology
- Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jan 2024 | $13M | — | Undisclosed | ↗ |
| CONVERTIBLEOther financing | Jun 2023 | $10M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Centrexion Therapeutics is 2.4K monthly website visits, down 17.2% over the last three months. Centrexion Therapeutics's team declined 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
InterWest Partners
NEA
Quan Capital- APArrowMark Partners
Other known investors1 additional known investor
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Centrexion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Centrexion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.